Levosimendan enhances cardiac performance in patients following cardiac surgery and cardiopulmonary bypass

被引：0

作者：

Warltier, DC ^{[1
]}

Nijhawan, N ^{[1
]}

Montgomery, MW ^{[1
]}

Nicolosi, AC ^{[1
]}

Pagel, PS ^{[1
]}

机构：

[1] Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA

来源：

XIII WORLD CONGRESS OF CARDIOLOGY: FREE PAPERS | 1998年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The hemodynamic effects of levosimendan, a new myofilament calcium sensitizing drug were studied in patients undergoing cardiac surgery and cardiopulmonary bypass. Levosimendan (18 or 36 mu g/kg bolus followed by 0.2 or 0.3 mu g/kg/min) was compared to placebo in 3 groups of patients (n=6 each). Levosimendan increased cardiac output and stroke volume and reduced systemic and pulmonary vascular resistance. The results indicate that levosimendan enhances cardiac performance and reduces ventricular afterload.

引用

页码：1015 / 1018

页数：4

共 50 条

[1] Levosimendan enhances cardiac performance in patients following cardiac surgery and cardiopulmonary bypass
E-P Sandell
N Nijhawan
PS Pagel
DC Warltier
Critical Care, 6 (Suppl 1):
[2] Levosimendan enhances cardiac performance in patients undergoing cardiac surgery: A double-blind trial
Nijhawan, N
Montgomery, MW
Nicolosi, AC
Pagel, PS
Warltier, DC
ANESTHESIA AND ANALGESIA, 1998, 86 (04): : SCA31 - SCA31
[3] Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial
Nijhawan, N
Nicolosi, AC
Montgomery, MW
Aggarwal, A
Pagel, PS
Warltier, DC
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (02) : 219 - 228
[4] Levosimendan Following Cardiac Surgery
Conte, Sean M.
Florisson, Daniel S.
De Bono, Joshua A.
Davies, Reece A.
Newcomb, Andrew E.
HEART LUNG AND CIRCULATION, 2019, 28 (03): : E19 - E20
[5] Postoperative complications following cardiac surgery with cardiopulmonary bypass
DM Atwell
I Welsby
WD White
SA King
MG Mythen
Critical Care, 1 (Suppl 1):
[6] Cardiopulmonary bypass in cardiac surgery
Baehner, T.
Boehm, O.
Probst, C.
Poetzsch, B.
Hoeft, A.
Baumgarten, G.
Knuefermann, P.
ANAESTHESIST, 2012, 61 (10): : 846 - 856
[7] ENHANCED CARDIAC-PERFORMANCE FOLLOWING CARDIOPULMONARY BYPASS
URZUA, J
ZURICK, AM
STARR, NJ
COSGROVE, DM
YARED, JP
ESTAFANOUS, FG
JOURNAL OF CARDIOVASCULAR SURGERY, 1985, 26 (01): : 53 - 58
[8] Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial
Mehta, Rajendra H.
Van Diepen, Sean
Meza, James
Bokesch, Paula
Leimberger, Jeffrey D.
Tourt-Uhlig, Sandra
Swartz, Merri
Parrotta, Jodi
Jankowich, Rachael
Hay, Douglas
Harrison, Robert W.
Fremes, Stephen
Goodman, Shaun G.
Luber, John
Toller, Wolfgang
Heringlake, Matthias
Anstrom, Kevin J.
Levy, Jerrold H.
Harrington, Robert A.
Alexander, John H.
AMERICAN HEART JOURNAL, 2016, 182 : 62 - 71
[9] Early platelet recovery following cardiac surgery with cardiopulmonary bypass
Van Poucke, Sven
Stevens, Kris
Wetzels, Rick
Kicken, Cecile
Verhezen, Paul
Theunissen, Maurice
Kuiper, Gerhardus
van Oerle, Rene
Henskens, Yvonne
Lance, Marcus
PLATELETS, 2016, 27 (08) : 751 - 757
[10] Serum concentrations of levosimendan and its metabolites OR-1855 and OR-1896 in cardiac surgery patients with cardiopulmonary bypass
Kipka, Hannah
Liebchen, Uwe
Huebner, Max
Hoefner, Georg
Frey, Otto
Wanner, Klaus T.
Kilger, Erich
Hagl, Christian
Tomasi, Roland
Mannell, Hanna
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11

← 1 2 3 4 5 →